Cyberonics panel date finalized
This article was originally published in The Gray Sheet
Executive Summary
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...